VBIV vs. KALA, BIVI, SYBX, COCP, TLPH, GLYC, TNXP, ORGS, AYTU, and APM
Should you be buying VBI Vaccines stock or one of its competitors? The main competitors of VBI Vaccines include KALA BIO (KALA), BioVie (BIVI), Synlogic (SYBX), Cocrystal Pharma (COCP), Talphera (TLPH), GlycoMimetics (GLYC), Tonix Pharmaceuticals (TNXP), Orgenesis (ORGS), Aytu BioPharma (AYTU), and Aptorum Group (APM). These companies are all part of the "pharmaceutical preparations" industry.
KALA BIO (NASDAQ:KALA) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, community ranking, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.
KALA BIO has higher earnings, but lower revenue than VBI Vaccines.
KALA BIO has a net margin of 0.00% compared to KALA BIO's net margin of -881.79%. VBI Vaccines' return on equity of -366.43% beat KALA BIO's return on equity.
VBI Vaccines received 202 more outperform votes than KALA BIO when rated by MarketBeat users. Likewise, 74.40% of users gave VBI Vaccines an outperform vote while only 66.67% of users gave KALA BIO an outperform vote.
In the previous week, KALA BIO and KALA BIO both had 4 articles in the media. VBI Vaccines' average media sentiment score of 1.12 beat KALA BIO's score of 0.94 indicating that KALA BIO is being referred to more favorably in the media.
KALA BIO currently has a consensus target price of $16.50, indicating a potential upside of 148.49%. Given VBI Vaccines' higher probable upside, equities research analysts plainly believe KALA BIO is more favorable than VBI Vaccines.
24.6% of KALA BIO shares are held by institutional investors. Comparatively, 12.3% of VBI Vaccines shares are held by institutional investors. 13.4% of KALA BIO shares are held by insiders. Comparatively, 10.4% of VBI Vaccines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
KALA BIO has a beta of -1.75, meaning that its stock price is 275% less volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
Summary
KALA BIO beats VBI Vaccines on 9 of the 14 factors compared between the two stocks.
Get VBI Vaccines News Delivered to You Automatically
Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VBIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VBI Vaccines Competitors List
Related Companies and Tools
